• 1
    Blumberg BS. Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci USA 1997; 94:71215.DOI: 10.1073/pnas.94.14.7121
  • 2
    Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:6715.
  • 3
    Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36:96272.
  • 4
    Zhang JY, Dai M, Wang X et al. A case–control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan China. Int J Epidemiol 1998; 27:5748.
  • 5
    Imai H, Nakano Y, Kiyosawa K, Tan EM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993; 71:2635.
  • 6
    Imai H, Chan EKL, Kiyosawa K, Fu XD, Tan EM. Novel nuclear antoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993; 92:241926.
  • 7
    Tan EM. Autoantibodies in pathology and cell biology. Cell 1991; 67:8412.
  • 8
    Tan EM, Chan EKL, Sullivan KF, Rubin RL. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 1988; 47:12141.
  • 9
    Tillman DM, Jou N-T, Hill RJ, Marion TN. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB × NZW) F1 mice. J Exp Med 1992; 176:76179.
  • 10
    Radic MZ & Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994; 12:487520.
  • 11
    Casiano CA, Landberg G, Ochs R, Tan EM. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci 1993; 106:104556.
  • 12
    Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeleton 1993; 26:21426.
  • 13
    Muro Y, Chan EKL, Landberg G, Tan EM. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Comm 1995; 207:102937.
  • 14
    Castets F, Rakitina T, Gaillard S, Moqrich A, Mattei MG, Monneron A, Zinedin. SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain. J Biol Chem 2000; 275:199707.DOI: 10.1074/jbc.m909782199
  • 15
    Moreno CS, Park S, Nelson K, Ashby D, Hubalek F, Lane WS, Pallas DC. WD40 repeat proteins striatin and S/G (2) nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A. J Biol Chem 2000; 275:525763.DOI: 10.1074/jbc.275.8.5257
  • 16
    Zhang JY, Chan EKL, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999; 189:110110.
  • 17
    Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999; 19:126270.
  • 18
    Mueller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997; 14:272933.
  • 19
    Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:91721.
  • 20
    Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58:180812.
  • 21
    Rohayem J, Diestelkoetter P, Weigle B et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000; 60:18157.
  • 22
    Old LJ & Chen Y-T. New paths in human cancer serology. J Exp Med 1989; 187:11637.
  • 23
    Sahin U & Türeci Ö, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92:118103.
  • 24
    Vogelstein B & Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9:13841.
  • 25
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:32331.
  • 26
    Hanahan D & Weinberg RA. The hallmarks of cancer. Cell 2000; 100:5770.
  • 27
    Tan EM. Autoantibodies in diagnosis and in identifying autoantigens. Immunologist 1999; 7:8592.
  • 28
    Rattner JB, Rees J, Whitehead CM et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997; 20:30819.
  • 29
    Chan EKL & Pollard KM. Autoantibodies to ribonucleoprotein particles by immunoblotting. In: RoseNR, Conway de MacarioE, FaheyJL, FriedmanH, PennGM, eds. Manual of clinical laboratory immunology. Washington DC: American Society for Microbiology, 1992:75561.
  • 30
    Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucl Acids Res 1984; 12:38795.
  • 31
    Huang X. On global sequence alignment. Comput Appl Biosci 1994; 10:22735.
  • 32
    Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52:416874.
  • 33
    Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89:343942.
  • 34
    Lenner P, Wiklund F, Emdin SO et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer 1999; 79:92732.
  • 35
    Raedle J, Oremek G, Truschnowitsch M et al. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Eur J Cancer 1998; 34:1198203.DOI: 10.1016/s0959-8049(98)00056-2
  • 36
    Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 1998; 4:214752.
  • 37
    Mitsudomi T, Suzuki S, Yatabe Y et al. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst 1998; 90:15638.
  • 38
    Montenarh M, Harlozinska A, Bar JK, Kartarius S, Gunther J, Sedlaczek P. p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer. Int J Oncol 1998; 13:60510.
  • 39
    Antic D & Keene JD. Messenger ribonucleoprotein complexes containing human ELAV proteins: interactions with cytoskeleton and translational apparatus. J Cell Sci 1998; 111:18397.
  • 40
    Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999; 9:27584.
  • 41
    Darnell RB. The importance of defining the paraneoplastic neurologic disorders. N Engl J Med 1999; 340:18313.
  • 42
    Antoine JC, Absi L, Honnorat J et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999; 56:1727.
  • 43
    Sahin U, Tureci O, Chen YT et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998; 78:3879.DOI: 10.1002/(sici)1097-0215(19981029)78:3<387::aid-ijc22>;2-o
  • 44
    Chen YT, Gure AO, Tsang S et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95:691923.DOI: 10.1073/pnas.95.12.6919
  • 45
    Stockert E, Jager E, Chen YT et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:134954.
  • 46
    Disis ML & Cheever MA. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996; 8:63742.
  • 47
    Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992; 140:85970.
  • 48
    Covini G, Von Muhlen CA, Pacchetti S, Colombo M, Chan EK, Tan EM. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol 1997; 26:125565.DOI: 10.1016/s0168-8278(97)80460-6
  • 49
    Kenan DJ, Query CC, Keene JD. RNA recognition: towards identifying determinants of specificity. Trends Biochem Sci 1991; 16:21420.
  • 50
    Burd CG & Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science 1994; 265:61521.
  • 51
    Doyle GA, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucl Acids Res 1998; 26:503644.DOI: 10.1093/nar/26.22.5036
  • 52
    Leeds P, Kren BT, Boylan JM et al. Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 1997; 14:127986.
  • 53
    Cariani E, Lasserre C, Seurin D et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988; 48:68449.
  • 54
    Yee D, Cullen KJ, Paik S et al. Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 1988; 48:66916.
  • 55
    Su TS, Liu WY, Han SH et al. Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 1989; 49:17737.